Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

copper Cu 64 TP3805

A peptide analog of pituitary adenylate cyclase-activating peptide (PACAP) radiolabeled with the positron-emitting radioisotope copper Cu 64, with potential diagnostic ability upon positron emission tomography (PET) imaging. The peptide moiety of copper Cu 64 TP3805 is able to bind to vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptors 1 (VPAC1). Upon PET imaging, the cancer cells expressing VPAC1 can be visualized and this may allow for early detection. The oncogenic product VPAC1 is overexpressed in a variety of cancer cell types, moreover, it is overexpressed in 100% of breast tumors at the onset of the cancer. Compared to other positron-emitting radioisotopes, Cu 64 has a longer half life.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Abbreviation:Cu-64-TP3805
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search